Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

Himisha Beltran, Davide Prandi, Juan Miguel Mosquera, Matteo Benelli, Loredana Puca, Joanna Cyrta, Clarisse Marotz, Eugenia Giannopoulou, Balabhadrapatruni V S K Chakravarthi, Sooryanarayana Varambally, Scott A Tomlins, David M Nanus (+7 others)
2016 Nature Medicine  
An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate cancer involves epithelial plasticity, wherein tumor cells demonstrate low to absent AR
doi:10.1038/nm.4045 pmid:26855148 pmcid:PMC4777652 fatcat:xtkrk3urzne4zfxgwueelyyvpi